Transparent Fluids and Enhanced Safety in Procedures: Insights from the OCULUS Study
Clinical Scorecard: Transparent Fluids and Enhanced Safety in Procedures: Insights from the OCULUS Study
At a Glance
| Category | Detail |
|---|
| Condition | Periprocedural management of GLP-1/GIP receptor agonists |
| Key Mechanisms | Real-time gastric visualization and predefined decision pathways |
| Target Population | Patients undergoing upper endoscopy while on GLP-1/GIP RAs |
| Care Setting | Procedural settings with moderate sedation or monitored anesthesia care |
Key Highlights
- First randomized clinical trial examining GLP-1/GIP RA management before upper endoscopy
- No clinically significant residual gastric volume observed with clear liquid diet
- Direct gastric visualization may improve procedural safety
- Clear liquid diet is a low-risk measure with broad applicability
- Caution advised in interpreting subgroup analyses due to early trial termination
Guideline-Based Recommendations
Diagnosis
Management
- Consider continuation of GLP-1/GIP RAs after risk stratification
- Implement clear liquid diet 24 hours prior to procedures
Monitoring & Follow-up
Risks
- Potential for periprocedural aspiration risk not fully mitigated by medication withholding
Patient & Prescribing Data
Patients receiving GLP-1/GIP RAs undergoing upper endoscopy
Clear liquid diet may influence gastric contents independently of medication management
Clinical Best Practices
- Utilize real-time gastric visualization during procedures
- Adopt clear liquid diet protocols for patients on GLP-1/GIP RAs
Related Resources & Content
